CL2022001989A1 - Formulación de anticuerpos estable - Google Patents
Formulación de anticuerpos estableInfo
- Publication number
- CL2022001989A1 CL2022001989A1 CL2022001989A CL2022001989A CL2022001989A1 CL 2022001989 A1 CL2022001989 A1 CL 2022001989A1 CL 2022001989 A CL2022001989 A CL 2022001989A CL 2022001989 A CL2022001989 A CL 2022001989A CL 2022001989 A1 CL2022001989 A1 CL 2022001989A1
- Authority
- CL
- Chile
- Prior art keywords
- antibody
- ebov
- present disclosure
- storage
- pharmaceutical formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062965786P | 2020-01-24 | 2020-01-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022001989A1 true CL2022001989A1 (es) | 2023-03-31 |
Family
ID=74858743
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022001989A CL2022001989A1 (es) | 2020-01-24 | 2022-07-22 | Formulación de anticuerpos estable |
| CL2023002560A CL2023002560A1 (es) | 2020-01-24 | 2023-08-30 | Formulación de anticuerpos estable |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023002560A CL2023002560A1 (es) | 2020-01-24 | 2023-08-30 | Formulación de anticuerpos estable |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12337199B2 (https=) |
| EP (1) | EP4093435A1 (https=) |
| JP (2) | JP7674369B2 (https=) |
| KR (1) | KR20220131923A (https=) |
| CN (1) | CN115243718A (https=) |
| AU (1) | AU2021210942A1 (https=) |
| BR (1) | BR112022014240A2 (https=) |
| CA (1) | CA3162569A1 (https=) |
| CL (2) | CL2022001989A1 (https=) |
| CO (1) | CO2022010254A2 (https=) |
| IL (1) | IL294375B1 (https=) |
| MX (1) | MX2022008949A (https=) |
| WO (1) | WO2021150829A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107635527B (zh) | 2015-03-10 | 2021-04-23 | 里珍纳龙药品有限公司 | 无菌刺穿系统和方法 |
| EP3487521A4 (en) | 2016-07-21 | 2020-07-01 | Emory University | ANTIBODIES AGAINST EBOLA VIRUS AND LIAISON AGENTS DERIVED THEREFROM |
| KR102540409B1 (ko) | 2017-05-05 | 2023-06-09 | 리제너론 파아마슈티컬스, 인크. | 자동 주사기 |
| USD1007676S1 (en) | 2021-11-16 | 2023-12-12 | Regeneron Pharmaceuticals, Inc. | Wearable autoinjector |
| TW202529831A (zh) | 2023-10-02 | 2025-08-01 | 美商再生元醫藥公司 | 藥物遞輸裝置安全系統 |
| US12514939B2 (en) | 2024-02-14 | 2026-01-06 | Alpha-9 Oncology, Inc. | Stable radiopharmaceutical compositions and uses thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0747045B2 (ja) | 1986-10-15 | 1995-05-24 | 株式会社大協精工 | 積層した注射器用滑栓 |
| JP3100727B2 (ja) | 1992-01-23 | 2000-10-23 | 株式会社大協精工 | 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品 |
| JP3172057B2 (ja) | 1995-04-05 | 2001-06-04 | 株式会社大協精工 | ラミネートゴム栓 |
| JP3512349B2 (ja) | 1999-01-29 | 2004-03-29 | 株式会社大協精工 | 柱状ゴム要素の成形型 |
| US6630144B1 (en) | 1999-08-30 | 2003-10-07 | The United States Of America As Represented By The Secretary Of The Army | Monoclonal antibodies to Ebola glycoprotein |
| US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
| US6875433B2 (en) | 2002-08-23 | 2005-04-05 | The United States Of America As Represented By The Secretary Of The Army | Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein |
| WO2009094755A1 (en) | 2008-02-01 | 2009-08-06 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Monoclonal antibodies for ebola and marburg viruses |
| AR070315A1 (es) * | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
| CA2741523C (en) | 2008-10-24 | 2022-06-21 | Jonathan S. Towner | Human ebola virus species and compositions and methods thereof |
| ES2676205T3 (es) * | 2011-03-31 | 2018-07-17 | Merck Sharp & Dohme Corp. | Formulaciones estables de anticuerpos para el receptor PD-1 humano de muerte programada y tratamientos relacionados |
| WO2014031718A1 (en) * | 2012-08-23 | 2014-02-27 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to tslp |
| JP6041580B2 (ja) * | 2012-08-28 | 2016-12-14 | 京セラ株式会社 | 電子機器、制御方法、及び制御プログラム |
| TWI710573B (zh) * | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
| TN2017000440A1 (en) | 2015-04-17 | 2019-04-12 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
| JP7402693B2 (ja) * | 2017-05-02 | 2023-12-21 | メルク・シャープ・アンド・ドーム・エルエルシー | 単独のおよびプログラム死受容体１（ｐｄ－１）抗体と組み合わされた抗ｔｉｇｉｔ抗体の安定な製剤、ならびにその使用方法 |
| KR20210005096A (ko) * | 2018-04-25 | 2021-01-13 | 메디뮨 리미티드 | 인간 항-pd-l1 항체의 제형 |
-
2021
- 2021-01-22 IL IL294375A patent/IL294375B1/en unknown
- 2021-01-22 BR BR112022014240A patent/BR112022014240A2/pt unknown
- 2021-01-22 CA CA3162569A patent/CA3162569A1/en active Pending
- 2021-01-22 KR KR1020227025939A patent/KR20220131923A/ko active Pending
- 2021-01-22 US US17/155,432 patent/US12337199B2/en active Active
- 2021-01-22 WO PCT/US2021/014524 patent/WO2021150829A1/en not_active Ceased
- 2021-01-22 EP EP21710081.7A patent/EP4093435A1/en active Pending
- 2021-01-22 JP JP2022543445A patent/JP7674369B2/ja active Active
- 2021-01-22 MX MX2022008949A patent/MX2022008949A/es unknown
- 2021-01-22 CN CN202180010566.0A patent/CN115243718A/zh active Pending
- 2021-01-22 AU AU2021210942A patent/AU2021210942A1/en active Pending
-
2022
- 2022-07-20 CO CONC2022/0010254A patent/CO2022010254A2/es unknown
- 2022-07-22 CL CL2022001989A patent/CL2022001989A1/es unknown
-
2023
- 2023-08-30 CL CL2023002560A patent/CL2023002560A1/es unknown
-
2025
- 2025-03-10 JP JP2025037025A patent/JP2025090691A/ja active Pending
- 2025-05-20 US US19/213,776 patent/US20250288665A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220131923A (ko) | 2022-09-29 |
| CO2022010254A2 (es) | 2022-08-09 |
| IL294375B1 (en) | 2026-02-01 |
| CN115243718A (zh) | 2022-10-25 |
| JP2023511080A (ja) | 2023-03-16 |
| JP7674369B2 (ja) | 2025-05-09 |
| WO2021150829A1 (en) | 2021-07-29 |
| AU2021210942A1 (en) | 2022-07-14 |
| IL294375A (en) | 2022-08-01 |
| US12337199B2 (en) | 2025-06-24 |
| MX2022008949A (es) | 2022-08-15 |
| BR112022014240A2 (pt) | 2022-12-13 |
| JP2025090691A (ja) | 2025-06-17 |
| US20210252146A1 (en) | 2021-08-19 |
| CL2023002560A1 (es) | 2024-03-01 |
| CA3162569A1 (en) | 2021-07-29 |
| EP4093435A1 (en) | 2022-11-30 |
| US20250288665A1 (en) | 2025-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022001989A1 (es) | Formulación de anticuerpos estable | |
| CO2019011021A2 (es) | Formulacion estable de anticuerpos | |
| ES2391798T3 (es) | Composición líquida farmacéutica de toxina botulínica con estabilidad mejorada | |
| CO2021011648A2 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-il-33 | |
| CO2020013552A2 (es) | Formulación de anticuerpos | |
| CU20190015A7 (es) | Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden | |
| JP2017222654A5 (https=) | ||
| MX2019008084A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r). | |
| CU20210081A7 (es) | Composición de partículas de arn lipoplejo | |
| AR108631A1 (es) | Formulación de neurotoxinas | |
| ATE554792T1 (de) | Stabiles wachstumshormon-flüssigformulierung | |
| MX2021002935A (es) | Formulacion de anticuerpos contra csf-1r. | |
| MX2019005137A (es) | Vacuna contra parvovirus porcino. | |
| ZA202204982B (en) | Stable formulation of integrin antibody | |
| CO2024014835A2 (es) | Formulaciones de anticuerpos contra el receptor de interleucina 4 (il-4r) | |
| MX2022014650A (es) | Formulacion que contiene anticuerpo. | |
| UY33652A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4(il-ar) | |
| BR112022004674A2 (pt) | Ácido canforsulfônico e combinações do mesmo com excipientes catiônicos como agentes de redução de viscosidade em formulações de proteína altamente concentradas | |
| CL2024003444A1 (es) | Formulación farmacéutica líquida estable que comprende un anticuerpo biespecífico anti-cd20/cd3 humano. | |
| BR112022024932A2 (pt) | Vacina contra vírus da influenza a suína compreendendo um constructo de ácido nucleico que possui uma ordem específica de genes | |
| JP7837512B2 (ja) | ウイルス安定化剤、ウイルス安定化剤用ゼラチン加水分解物およびウイルス含有組成物 | |
| AR127750A1 (es) | Una composición antimicrobiana | |
| CL2022003586A1 (es) | Formulaciones de anticuerpo de activina a y métodos para utilizarlas | |
| AR131148A1 (es) | Composiciones de insulina de acción rápida (variantes de las mismas) | |
| UY37260A (es) | Formulación de neurotoxina que comprende un tensioactivo, un aminoácido seleccionado de triptófano o tirosina, y un tampón |